These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1194 related articles for article (PubMed ID: 28742225)

  • 1. Efficacy and safety of lixisenatide in a predominantly Asian population with type 2 diabetes insufficiently controlled with basal insulin: The GetGoal-L-C randomized trial.
    Yang W; Min K; Zhou Z; Li L; Xu X; Zhu D; Venkateshwar Rao A; Murthy LS; Zhang N; Li I; Niemoeller E; Shang S
    Diabetes Obes Metab; 2018 Feb; 20(2):335-343. PubMed ID: 28742225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: a randomized, double-blind, placebo-controlled, 24-week trial (GetGoal-M-Asia).
    Yu Pan C; Han P; Liu X; Yan S; Feng P; Zhou Z; Lv X; Tian H; Jin Kui Y; Su B; Shang S; Niemoeller E
    Diabetes Metab Res Rev; 2014 Nov; 30(8):726-35. PubMed ID: 24639432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of lixisenatide as add-on therapy to basal insulin in older adults with type 2 diabetes in the GetGoal-O Study.
    Dailey GE; Dex TA; Roberts M; Liu M; Meneilly GS
    J Diabetes; 2019 Dec; 11(12):971-981. PubMed ID: 31094074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of once-daily glucagon-like peptide-1 receptor agonist lixisenatide as an add-on treatment to basal insulin in Asian and white adults with type 2 diabetes mellitus: An individual-level pooled analysis of phase III studies.
    Liu F; Liu Y; Liu M; Wu G; Zhang M; Zhang X; Cui N; Yin H; Chen L
    J Diabetes Investig; 2021 Aug; 12(8):1386-1394. PubMed ID: 33475222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P).
    Pinget M; Goldenberg R; Niemoeller E; Muehlen-Bartmer I; Guo H; Aronson R
    Diabetes Obes Metab; 2013 Nov; 15(11):1000-7. PubMed ID: 23627775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction of postprandial glucose by lixisenatide vs sitagliptin treatment in Japanese patients with type 2 diabetes on background insulin glargine: A randomized phase IV study (NEXTAGE Study).
    Yamada Y; Senda M; Naito Y; Tamura M; Watanabe D; Shuto Y; Urita Y
    Diabetes Obes Metab; 2017 Sep; 19(9):1252-1259. PubMed ID: 28345162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia).
    Seino Y; Min KW; Niemoeller E; Takami A;
    Diabetes Obes Metab; 2012 Oct; 14(10):910-7. PubMed ID: 22564709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lixisenatide reduces glycaemic variability in insulin-treated patients with type 2 diabetes.
    Umpierrez GE; O'Neal D; DiGenio A; Goldenberg R; Hernandez-Triana E; Lin J; Park CY; Renard E; Kovatchev B
    Diabetes Obes Metab; 2017 Sep; 19(9):1317-1321. PubMed ID: 28256054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION-7 randomized study.
    Guja C; Frías JP; Somogyi A; Jabbour S; Wang H; Hardy E; Rosenstock J
    Diabetes Obes Metab; 2018 Jul; 20(7):1602-1614. PubMed ID: 29473704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S).
    Rosenstock J; Hanefeld M; Shamanna P; Min KW; Boka G; Miossec P; Zhou T; Muehlen-Bartmer I; Ratner RE
    J Diabetes Complications; 2014; 28(3):386-92. PubMed ID: 24650952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lixisenatide as add-on to oral anti-diabetic therapy: an effective treatment for glycaemic control with body weight benefits in type 2 diabetes.
    Raccah D; Gourdy P; Sagnard L; Ceriello A
    Diabetes Metab Res Rev; 2014 Nov; 30(8):742-8. PubMed ID: 24687427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamics of the glucagon-like peptide-1 receptor agonist lixisenatide in Japanese and Caucasian patients with type 2 diabetes mellitus poorly controlled on sulphonylureas with/without metformin.
    Seino Y; Takami A; Boka G; Niemoeller E; Raccah D;
    Diabetes Obes Metab; 2014 Aug; 16(8):739-47. PubMed ID: 24524806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin.
    Kapitza C; Forst T; Coester HV; Poitiers F; Ruus P; Hincelin-Méry A
    Diabetes Obes Metab; 2013 Jul; 15(7):642-9. PubMed ID: 23368510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beneficial effect of lixisenatide after 76 weeks of treatment in patients with type 2 diabetes mellitus: A meta-analysis from the GetGoal programme.
    Broglio F; Mannucci E; Napoli R; Nicolucci A; Purrello F; Nikonova E; Stager W; Trevisan R
    Diabetes Obes Metab; 2017 Feb; 19(2):248-256. PubMed ID: 27762096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Lixisenatide in Japanese Patients with Type 2 Diabetes Insufficiently Controlled with Basal Insulin±Sulfonylurea: A Subanalysis of the GetGoal-L-Asia Study.
    Seino Y; Ikeda Y; Niemoeller E; Watanabe D; Takagi H; Yabe D; Inagaki N
    Horm Metab Res; 2015 Nov; 47(12):895-900. PubMed ID: 26039935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L).
    Riddle MC; Aronson R; Home P; Marre M; Niemoeller E; Miossec P; Ping L; Ye J; Rosenstock J
    Diabetes Care; 2013 Sep; 36(9):2489-96. PubMed ID: 23628617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1).
    Riddle MC; Forst T; Aronson R; Sauque-Reyna L; Souhami E; Silvestre L; Ping L; Rosenstock J
    Diabetes Care; 2013 Sep; 36(9):2497-503. PubMed ID: 23564915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lixisenatide treatment for older patients with type 2 diabetes mellitus uncontrolled on oral antidiabetics: meta-analysis of five randomized controlled trials.
    Hanefeld M; Berria R; Lin J; Aronson R; Darmon P; Evans M; Van Gaal L
    Adv Ther; 2014 Aug; 31(8):861-72. PubMed ID: 25143188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial.
    Rosenstock J; Guerci B; Hanefeld M; Gentile S; Aronson R; Tinahones FJ; Roy-Duval C; Souhami E; Wardecki M; Ye J; Perfetti R; Heller S;
    Diabetes Care; 2016 Aug; 39(8):1318-28. PubMed ID: 27222510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9).
    Pozzilli P; Norwood P; Jódar E; Davies MJ; Ivanyi T; Jiang H; Woodward DB; Milicevic Z
    Diabetes Obes Metab; 2017 Jul; 19(7):1024-1031. PubMed ID: 28294499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 60.